Ann: CEO Presentation to Bioshares Conference, page-55

Chris Behrenbruch is without a doubt one of the best executive leaders in ASX biotech, if not globally.

We are fortunate to have him guiding FTT as part of the Exceutive leadership team to what I believe will - in the not to distant future - be significant commercial success.

Anyone who isn't familiar with his extensive achievements in global biotech should read this:

Biography​

Dr. Behrenbruch received a degree in electrical engineering and computer science from Monash University and received a D.Phil (Ph.D) in biomedical engineering from Oxford University in Sir Prof. Mike Brady’s “Medical Vision Laboratory” in the field of imaging and diagnosis of breast cancer. He also took additional graduate study in computational biology and genomics at Stanford University. He holds a Master of Business Administration (MBA) jointly awarded from New York University and the London School of Economics (TRIUM program) and has a strong background in corporate finance and negotiation. Dr. Behrenbruch holds over 60 peer-reviewed publications and patents in the field of medical informatics, biotechnology and nanotechnology.
A serial entrepreneur, Dr. Behrenbruch started his career with BHP Asia (Vietnam) in the oil and gas industry and Siemens Telecommunications (Asia/Pacific). In the late 90’s, he was involved in starting several UK-based companies including Oxford Medical Image Analysis and Mirada Solutions. In 2003 during his term as CEO, Mirada Solutions was sold to CTI Molecular Imaging (NASDAQ: CTMI) and he became President of the IT and bioinformatics division of CTI as well as Managing Director of CTI’s European operations. In 2005, CTI became part of Siemens Medical Solutions in a $1.1B acquisition and Dr. Behrenbruch was a Vice President at Siemens during the 18-month post-merger integration, with a focus on clinical applications and product marketing. His responsibilities at Siemens included luminary customer relationships and key corporate-level interfacing projects such as GlaxoSmithKline’s Hammersmith imaging centre and Singapore’s “Biopolis”.
From 2007–9, Dr. Behrenbruch was a Professor in the Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, at the University of California, Los Angeles (UCLA). His appointment at UCLA followed a successful track record in commercializing biotechnology, healthcare IT and medical devices. His laboratory focused on the technical and clinical challenges of introducing new device, instrumentation and nanotechnology solutions into the healthcare practice and he continues to teach in the area of life sciences commercialization and technology transfer. Dr. Behrenbruch was also a visiting academic at the Zhejiang-California Nanosystems Institute, Zhejiang University in Hangzhou, China (2006-2009) and has taught entrepreneurship classes at UCLA (David Geffen School of Medicine, Henry Samueli School of Engineering and Applied Science and Anderson School of Business), Oxford University (Saïd Business School), California Institute of Technology (Caltech), ESMT (Berlin), Zhejiang University (China) and the University of Sydney. He was formerly a UC Discovery Mentor (Univ. of California’s entrepreneurship program) and is a regular reviewer for US National Institutes of Health / National Science Foundation grants and several leading science and medical journals.
Parallel to his prior academic role at UCLA, Dr. Behrenbruch was a Founder and Managing Partner of Momentum Biosciences LLC, a Los Angeles-based early stage venturing and business advisory group. Momentum was established as a faculty-led seed fund to accelerate spin-out companies from Los Angeles-area institutions, such as UCLA, the University of Southern California and Caltech in the field of medical devices, biotechnology and nanotechnology. Momentum Biosciences manages a fully staffed and equipped biotechnology incubator facility in Culver City (Los Angeles) in close proximity to UCLA and is currently managing or mentoring half a dozen Caltech and UCLA spin-out projects in diagnostics (imaging & IVD), drug delivery systems and novel therapeutics.
In June 2009, Dr. Behrenbruch left his management role at Momentum to take the position of CEO at ImaginAb, Inc (until Feb, 2015). ImaginAb was the first Momentum portfolio company to “graduate” from its venture accelerator program and has raised a total of $50m in venture capital (lead by Novartis Venture Funds) and non-dilutive financing. ImaginAb’s sister company Sofie Biosciences also attracted onward financing. He is also a co-founder and (formerly) non-executive director of Mirada Medical (a management buy-out from Siemens) and Radius Health (now Adaptix Ltd) a nanomaterials company in the area of miniaturized MEMS X-ray sources for medical imaging and security applications. He formerly served as a non-executive Director of the Brussels-based Oncidium Foundation and was the non-executive Chairman of Cell Therapies Pty Ltd, a private-public partnership with the Peter MacCallum Cancer Center in Melbourne, Australia.
Dr. Behrenbruch was recognized by the World Economic Forum as a 2011 Young Global Leader, one of 200 individuals selected by the WEF each year to explore issues related to global development and sustainability. He was also the recipient of the 2012 Advance Global Australian of the Year award in the field of Biotechnology, is a 2013 PharmaVoice 100 awardee and received the 2014 Distringuished Alumi Award (Engineering) from Monash University. He is currently an adjunct Professor at RMIT University (Melbourne, Australia) and a Vice-Chancellor’s Professorial Fellow at Monash University. Dr. Behrenbruch is a member of the Monash Engineering Foundation Board.


ADVANCE: Connecting Global Australians:
​

Entrepreneur and Monash University alumnus Christian Behrenbruch is recognised internationally for commercialisation achievements in healthcare IT, medical device and biotechnology domains.

He has particular expertise in university-industry technology transfer and has fostered entrepreneurship and commercialisation at universities internationally.

To suggest he hasn't covered off the commercial relationship between QUT BlueBox and FTT is, IMO, disingenuous.



​